Fighting Post-COVID and ME/CFS – development of curative therapies

Carmen Scheibenbogen; Judith Theresia Bellmann-Strobl; Cornelia Heindrich; Kirsten Wittke; Elisa Stein; Christiana Franke; Harald Prüss; Hannah Preßler; Marie Luise Machule; Heinrich Audebert; Carsten Finke; Hanna Gwendolyn Zimmermann; Birgit Sawitzki; Christian Meisel; Markus Toelle; Anne Krueger; Anna C. Aschenbrenner; Joachim L. Schultze; Marc D. Beyer; Markus Ralser; Michael Mülleder; Leif Erik Sander; Frank Konietschke; Friedemann Paul; Silvia Stojanov; Lisa Bruckert; Dennis M. Hedderich; Franziska Knolle; Gabriela Riemekasten; Maria J.G.T. Vehreschild; Oliver A. Cornely; Uta Behrends; Susen Burock

doi:10.3389/fmed.2023.1194754

Fighting Post-COVID and ME/CFS – development of curative therapies

Carmen Scheibenbogen, Judith Theresia Bellmann-Strobl, Cornelia Heindrich^*, Kirsten Wittke, Elisa Stein, Christiana Franke, Harald Prüss, Hannah Preßler, Marie Luise Machule, Heinrich Audebert, Carsten Finke, Hanna Gwendolyn Zimmermann, Birgit Sawitzki, Christian Meisel, Markus Toelle, Anne Krueger, Anna C. Aschenbrenner, Joachim L. Schultze, Marc D. Beyer, Markus RalserMichael Mülleder, Leif Erik Sander, Frank Konietschke, Friedemann Paul, Silvia Stojanov, Lisa Bruckert, Dennis M. Hedderich, Franziska Knolle, Gabriela Riemekasten, Maria J.G.T. Vehreschild, Oliver A. Cornely, Uta Behrends, Susen Burock

^*Corresponding author for this work

Department of Rheumatology and Clinical Immunology

43 Citations (Scopus)

Abstract

The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.

Original language	English
Article number	1194754
Journal	Frontiers in medicine
Volume	10
ISSN	2296-858X
DOIs	https://doi.org/10.3389/fmed.2023.1194754
Publication status	Published - 2023

Funding

The clinical trial platform is funded by the Bundesministerium für Bildung und Forschung (German Ministry of Education and Research), Grant 01EP2201.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

DFG Research Classification Scheme

2.21-05 Immunology

Coronavirus related work

Research on SARS-CoV-2 / COVID-19

Access to Document

10.3389/fmed.2023.1194754

Cite this

Scheibenbogen, C., Bellmann-Strobl, J. T., Heindrich, C., Wittke, K., Stein, E., Franke, C., Prüss, H., Preßler, H., Machule, M. L., Audebert, H., Finke, C., Zimmermann, H. G., Sawitzki, B., Meisel, C., Toelle, M., Krueger, A., Aschenbrenner, A. C., Schultze, J. L., Beyer, M. D., ... Burock, S. (2023). Fighting Post-COVID and ME/CFS – development of curative therapies. Frontiers in medicine, 10, Article 1194754. https://doi.org/10.3389/fmed.2023.1194754

@article{23867281ca4146349a04e0eb52e00f96,

title = "Fighting Post-COVID and ME/CFS – development of curative therapies",

abstract = "The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.",

author = "Carmen Scheibenbogen and Bellmann-Strobl, \{Judith Theresia\} and Cornelia Heindrich and Kirsten Wittke and Elisa Stein and Christiana Franke and Harald Pr{\"u}ss and Hannah Pre{\ss}ler and Machule, \{Marie Luise\} and Heinrich Audebert and Carsten Finke and Zimmermann, \{Hanna Gwendolyn\} and Birgit Sawitzki and Christian Meisel and Markus Toelle and Anne Krueger and Aschenbrenner, \{Anna C.\} and Schultze, \{Joachim L.\} and Beyer, \{Marc D.\} and Markus Ralser and Michael M{\"u}lleder and Sander, \{Leif Erik\} and Frank Konietschke and Friedemann Paul and Silvia Stojanov and Lisa Bruckert and Hedderich, \{Dennis M.\} and Franziska Knolle and Gabriela Riemekasten and Vehreschild, \{Maria J.G.T.\} and Cornely, \{Oliver A.\} and Uta Behrends and Susen Burock",

note = "Publisher Copyright: Copyright {\textcopyright} 2023 Scheibenbogen, Bellmann-Strobl, Heindrich, Wittke, Stein, Franke, Pr{\"u}ss, Pre{\ss}ler, Machule, Audebert, Finke, Zimmermann, Sawitzki, Meisel, Toelle, Krueger, Aschenbrenner, Schultze, Beyer, Ralser, M{\"u}lleder, Sander, Konietschke, Paul, Stojanov, Bruckert, Hedderich, Knolle, Riemekasten, Vehreschild, Cornely, Behrends and Burock.",

year = "2023",

doi = "10.3389/fmed.2023.1194754",

language = "English",

volume = "10",

journal = "Frontiers in medicine",

issn = "2296-858X",

}

Scheibenbogen, C, Bellmann-Strobl, JT, Heindrich, C, Wittke, K, Stein, E, Franke, C, Prüss, H, Preßler, H, Machule, ML, Audebert, H, Finke, C, Zimmermann, HG, Sawitzki, B, Meisel, C, Toelle, M, Krueger, A, Aschenbrenner, AC, Schultze, JL, Beyer, MD, Ralser, M, Mülleder, M, Sander, LE, Konietschke, F, Paul, F, Stojanov, S, Bruckert, L, Hedderich, DM, Knolle, F, Riemekasten, G, Vehreschild, MJGT, Cornely, OA, Behrends, U & Burock, S 2023, 'Fighting Post-COVID and ME/CFS – development of curative therapies', Frontiers in medicine, vol. 10, 1194754. https://doi.org/10.3389/fmed.2023.1194754

TY - JOUR

T1 - Fighting Post-COVID and ME/CFS – development of curative therapies

AU - Scheibenbogen, Carmen

AU - Bellmann-Strobl, Judith Theresia

AU - Heindrich, Cornelia

AU - Wittke, Kirsten

AU - Stein, Elisa

AU - Franke, Christiana

AU - Prüss, Harald

AU - Preßler, Hannah

AU - Machule, Marie Luise

AU - Audebert, Heinrich

AU - Finke, Carsten

AU - Zimmermann, Hanna Gwendolyn

AU - Sawitzki, Birgit

AU - Meisel, Christian

AU - Toelle, Markus

AU - Krueger, Anne

AU - Aschenbrenner, Anna C.

AU - Schultze, Joachim L.

AU - Beyer, Marc D.

AU - Ralser, Markus

AU - Mülleder, Michael

AU - Sander, Leif Erik

AU - Konietschke, Frank

AU - Paul, Friedemann

AU - Stojanov, Silvia

AU - Bruckert, Lisa

AU - Hedderich, Dennis M.

AU - Knolle, Franziska

AU - Riemekasten, Gabriela

AU - Vehreschild, Maria J.G.T.

AU - Cornely, Oliver A.

AU - Behrends, Uta

AU - Burock, Susen

N1 - Publisher Copyright: Copyright © 2023 Scheibenbogen, Bellmann-Strobl, Heindrich, Wittke, Stein, Franke, Prüss, Preßler, Machule, Audebert, Finke, Zimmermann, Sawitzki, Meisel, Toelle, Krueger, Aschenbrenner, Schultze, Beyer, Ralser, Mülleder, Sander, Konietschke, Paul, Stojanov, Bruckert, Hedderich, Knolle, Riemekasten, Vehreschild, Cornely, Behrends and Burock.

PY - 2023

Y1 - 2023

N2 - The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.

AB - The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.

UR - https://www.scopus.com/pages/publications/85164388992

U2 - 10.3389/fmed.2023.1194754

DO - 10.3389/fmed.2023.1194754

M3 - Journal articles

AN - SCOPUS:85164388992

SN - 2296-858X

VL - 10

JO - Frontiers in medicine

JF - Frontiers in medicine

M1 - 1194754

ER -

Fighting Post-COVID and ME/CFS – development of curative therapies

Abstract

Funding

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Coronavirus related work

Access to Document

Other files and links

Fingerprint

Cite this